Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: The role of nerve growth factor (NGF) receptors

Endocrinology

Volumn 154, Issue 7, 2013, Pages 2446-2456

  Anagnostopoulou, Vasileia ^a   Pediaditakis, Iosif ^a,b   Alkahtani, Saad ^c   Alarifi, Saud A ^c   Schmidt, Eva Maria ^d   Lang, Florian ^d   Gravanis, Achille ^a,b   Charalampopoulos, Ioannis ^a   Stournaras, Christos ^a,d  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR; PRASTERONE; RHO FACTOR; TESTOSTERONE; TROPOMYOSIN;

APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; DOWN REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; PATHOPHYSIOLOGY; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COLONIC NEOPLASMS; DEHYDROEPIANDROSTERONE; HUMANS; MALE; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; PC12 CELLS; PROSTATIC NEOPLASMS; RATS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 84879321180     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2249     Document Type: Article

References (60)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
2. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33:270-298. (Pubitemid 43849931)
3. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:C113-C118.
4. Slattery ML, Sweeney C, Murtaugh M, et al. Associations between ERα, ERβ, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2936-2942. (Pubitemid 43068828)
5. Gu S, Papadopoulou N, Gehring EM, et al. Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo. Mol Cancer. 2009;8:114.
6. Hébert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7:653-659. (Pubitemid 28374594)
7. Nyce JW, Magee PN, Hard GC, Schwartz AG. Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. Carcinogenesis. 1984;5:57-62. (Pubitemid 14197927)
8. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol. 2003;85:469-472. (Pubitemid 37011123)
9. Gray NE, Liu X, Choi R, Blackman MR, Arnold JT. Endocrine-immune- paracrine interactions in prostate cells as targeted by phytomedicines. Cancer Prev Res (Phila). 2009;2:134-142.
10. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006;290:E952-60.
11. Arnold JT, Blackman MR. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer? Endocrinology. 2005;146:4565-4567. (Pubitemid 41447503)
12. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol. 2007;21:2855-2863. (Pubitemid 350223500)
13. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308. (Pubitemid 38501396)
14. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010;151:3514-3520.
15. Widstrom RL, Dillon JS. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Semin Reprod Med. 2004;22:289-298. (Pubitemid 40030079)
16. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev. 2006;38:89-116. (Pubitemid 43739001)
17. Chen F, Knecht K, Birzin E, et al. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005;146:4568-4576. (Pubitemid 41446594)
18. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell. 1994;77:627-638. (Pubitemid 24175600)
19. Klein R. Role of neurotrophins in mouse neuronal development. FASEB J. 1994;8:738-744. (Pubitemid 24229768)
20. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-370. (Pubitemid 38579482)
21. Krüttgen A, Schneider I, Weis J. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol. 2006;16:304-310.
22. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci. 1996;19:463-489. (Pubitemid 26080836)
23. Chao MV, Bothwell MA, et al. Gene transfer and molecular cloning of the human NGF receptor. Science. 1986;232:518-521. (Pubitemid 16052370)
24. Connolly JL, Greene LA, Viscarello RR, Riley WD. Rapid, sequential changes in surface morphology of PC12 pheochromocytoma cells in response to nerve growth factor. J Cell Biol. 1979;82:820-827. (Pubitemid 10222852)
25. Herrup K, Thoenen H. Properties of the nerve growth factor receptor of a clonal line of rat pheochromocytoma (PC12) cells. Exp Cell Res. 1979;121:71-78. (Pubitemid 9224635)
26. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237:1154-1162. (Pubitemid 17124912)
27. Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol. 2006;21:850-858. (Pubitemid 43793283)
28. Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res. 2001;7:105-112. (Pubitemid 32110212)
29. Delsite R, Djakiew D. Characterization of nerve growth factor precursor protein expression by human prostate stromal cells: a role in selective neurotrophin stimulation of prostate epithelial cell growth. Prostate. 1999;41:39-48. (Pubitemid 29390414)
30. Rende M, Rambotti MG, Stabile AM, et al. Novel localization of low affinity NGF receptor (p75) in the stroma of prostate cancer and possible implication in neoplastic invasion: an immunohistochemical and ultracytochemical study. Prostate. 2010;70:555-561.
31. Miknyoczki SJ, Wan W, Chang H, et al. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res. 2002;8:1924-1931. (Pubitemid 34633755)
32. Kampa M, Kogia C, Theodoropoulos PA, et al. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. Mol Cancer Ther. 2006;5:1342-1351. (Pubitemid 43881328)
33. Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A, Stournaras C. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. Exp Cell Res. 2008;314:3162-3174.
34. Papadopoulou N, Charalampopoulos I, Anagnostopoulou V, et al. Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-κB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Mol Cancer. 2008;7:88.
35. Gu S, Papadopoulou N, Nasir O, et al. Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med. 2011;17:48-58.
36. Lang F, Perrotti N, Stournaras C. Colorectal carcinoma cells - regulation of survival and growth by SGK1. Int J Biochem Cell Biol. 2010;42:1571-1575.
37. Papakonstanti EA, Kampa M, Castanas E, Stournaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol. 2003;17:870-881. (Pubitemid 36539577)
38. Charalampopoulos I, Tsatsanis C, Dermitzaki E, et al. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci USA. 2004;101:8209-8214. (Pubitemid 38698079)
39. Charalampopoulos I, Margioris AN, Gravanis A. Neurosteroid dehydroepiandrosterone exerts anti-apoptotic effects by membranemediated, integrated genomic and non-genomic pro-survival signaling pathways. J Neurochem. 2008;107:1457-1469.
40. Charalampopoulos I, Alexaki VI, Lazaridis I, et al. G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone. FASEB J. 2006;20:577-579. (Pubitemid 46671255)
41. Charalampopoulos I, Dermitzaki E, Vardouli L, et al. Dehydroepiandrosterone sulfate and allopregnanolone directly stimulate catecholamine production via induction of tyrosine hydroxylase and secretion by affecting actin polymerization. Endocrinology. 2005;146:3309-3318. (Pubitemid 41058102)
42. Lazaridis I, Charalampopoulos I, et al. Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis. PLoS Biol. 2011;9:e1001051.
43. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006;580:2294-2300. (Pubitemid 43675636)
44. Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 2000;85:932-944. (Pubitemid 30242804)
45. Nikoletopoulou V, Lickert H, Frade JM, et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature. 2010;467:59-63.
46. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer. 2005;12:511-532. (Pubitemid 41482991)
47. Labrie F, Dupont A, Simard J, Luu-The V, Bélanger A. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol. 1993;24:94-105. (Pubitemid 23320413)
48. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature. 1983;303:767-770. (Pubitemid 13054488)
49. Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6:347-360. (Pubitemid 39361436)
50. Koukouritaki S, Margioris A, Gravanis A, Hartig R, Stournaras C. Dexamethasone induces actin polymerization in human endometrial cells without affecting its synthesis. J Cell Biochem. 1997;65:492-500. (Pubitemid 27240915)
51. Koukouritaki SB, Gravanis A, Stournaras C. Tyrosine phosphorylation of focal adhesion kinase and paxillin regulates the signaling mechanism of the rapid nongenomic action of dexamethasone on actin cytoskeleton. Mol Med. 1999;5:731-742. (Pubitemid 32937033)
52. Papadopoulou N, Papakonstanti EA, Kallergi G, Alevizopoulos K, Stournaras C. Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. IUBMB Life. 2009;61:56-61.
53. Hatzoglou A, Kampa M, Kogia C, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab. 2005;90:893-903. (Pubitemid 40279214)
54. Yamashita T, Tucker KL, Barde YA. Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron. 1999;24:585-593.
55. Harel L, Costa B, Fainzilber M. On the death Trk. Dev Neurobiol. 2010;70:298-303.
56. Calogeropoulou T, Avlonitis N, Minas V, et al. Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity. J Med Chem. 2009;52:6569-6587.
57. Weeraratna AT, Dalrymple SL, Lamb JC, et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res. 2001;7:2237-2245. (Pubitemid 32751620)
58. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA. 1995;92:3439-3443.
59. Charalampopoulos I, Vicario A, Pediaditakis I, Gravanis A, Simi A, Ibáñez CF. Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor. Cell Rep. 2012;2:1563-1570.
60. Vilar M, Charalampopoulos I, Kenchappa RS, et al. Activation of the p75 neurotrophin receptor through conformational rear-rangement of disulphide-linked receptor dimers. Neuron. 2009;62:72-83. Technology, and Innovation